MELBOURNE, Australia--(BUSINESS WIRE)--
Australian-based drug and development company Agenix Limited (ASX:AGX)
today announced the appointment of Dr Paul Resnick as business advisor.
Dr Resnick will initially focus on the Company's revolutionary blood
clot diagnostic ThromboView®.
Dr Resnick is the former Vice President of Business Development at
privately held US-based biotechnology business Intellikine Inc where he
played a key role in securing a $489 million program licensing deal and
the subsequent sale of the business in December 2011 to Japan's Takeda
Pharmaceutical Co for $310 million.
Before joining Intellikine, Dr Resnick was Senior Director of Worldwide
Business Development at Pfizer Inc (NYSE: PFE). He previously held roles
at Rinat Neuroscience, InterMune, Roche Pharmaceuticals and practiced
medicine. At Rinat Neuroscience, he played a key role in its acquisition
by Pfizer Inc.
Agenix Chairman and Chief Executive Officer Nicholas Weston said, "Paul
adds significant depth and experience to our team and will provide
strategic guidance and negotiation support as we progress our promising
commercial and clinical programs."
"Agenix is continuously engaged with potential strategic corporate
partners in multiple geographies. Paul will help us manage this
important process in a timely and efficient manner to achieve the best
possible results that create shareholder value."
Dr Resnick said "I see significant unrecognized potential and value in
Agenix and the exciting assets it has developed. There is a compelling
proposition in ThromboView's strong clinical safety and efficacy profile
and its potential value in a range of clinical applications."
Follow Agenix on Twitter or LinkedIn.
ThromboView® is a registered trademark of Agen Biomedical
Limited, a wholly owned subsidiary of Agenix Limited.
Agenix is a public, clinical-stage company focused on the discovery and
development of innovative monoclonal antibody blood clot diagnostics,
and small molecule drugs for the treatment of hepatitis B and other
serious diseases. Agenix's most advanced diagnostic candidate,
ThromboView®, a novel radio-labelled monoclonal antibody imaging agent,
has completed two Phase 2 clinical trials, and is ideal to diagnose
patients indicated for suspected acute pulmonary embolism (PE), with a
positive D-dimer blood test or moderate to high pre-test probability of
PE, as a replacement diagnostic test for patients with suspected PE
where V/Q scans are a first line choice and are unlikely to deliver a
diagnostic result, as a confirmatory diagnostic where CT is used as a
first-line diagnostic test, the scan result is negative and the clinical
probability of disease is high or moderate and as a replacement
diagnostic where CTPA is an inappropriate choice based on radiation
exposure, renal impairment or contrast allergy. Agenix is also
developing AGX 1009, a next-generation reverse transcriptase inhibitor
(NtRTI) prodrug of tenofovir, for which a CTA is planned to be filed
with the Chinese FDA in the second half of 2012 and for which the
Company plans to advance into Phase 1 in the second half of 2013. Agenix
owns all the patent rights to both ThromboView® and AGX 1009. In August
2010, Agenix entered into a collaborative partnership with the Institute
of Medicinal Biotechnology of the Chinese Academy of Medical Sciences,
part of the Ministry of Health to purchase AGX 1009 and preclinical work
is being conducted in Beijing, China by the Institute of Pharmacology
and Toxicology of the Academy of Military Medical Sciences. Agenix has
taken successfully from laboratory to global commercialisation then
commercial exit more than 20 products over four technology platforms
since listing on the Australian Securities Exchange in 1987.